PTC Therapeutics is a US pharmaceutical company focused on the development of orally administered small molecule drugs that regulate gene expression by targeting post-translational control (PTC) mechanisms in orphan diseases.
Since 2003, PTC has been working on a drug for Duchenne muscular dystrophy.
In September 2009, PTC has entered into an agreement with Roche for the development of orally bioavailable small molecules for central nervous system diseases.
As of May 2016, PTC portfolio includes small-molecule compounds for treatment of spinal muscular atrophy (RG7916) and Duchenne muscular dystrophy (Ataluren and another exon skipping compound).
